Citations

Showing 10 of 108094 citations.

An introduction to key performance indicators for medical physicists
DiCostanzo, D.J. , Kumaraswamy, Lalith K. , Shuman, Jillian, Pavord, Daniel C. , Hu, Yanle , Waite‐Jones, Christopher G., Hsu, Annie , Jordan, David W.

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 13, 2022 | Volume: 23 | Issue: 8 | Pages: No page available

10.1002/acm2.13718 | PMID 35829667 Get It

AbstractQualified medical physicists (QMPs) are in a unique position to influence the creation and application of key performance indicators (KPIs) across diverse practices in health care. Developing KPIs requires the involvement of stakeholders in the area of interest. Fundamentally, KPIs should provide actionable information for the stakeholders using or viewing them. During development, it is important to strongly consider the underlying data collection for the KPI, making it automatic whenever possible. Once the KPI has been validated, it is important to setup a review cycle and be prepared to adjust the underlying data or action levels if the KPI is not performing as intended. Examples of specific KPIs for QMPs of common scopes of practice are provided to act as models to aid in implementation. KPIs are a useful tool for QMPs, regardless of the scope of practice or practice environment, to enhance the safety and quality of care being delivered.
Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia
Wang, Liping , Lin, Guang , Zuo, Zhongyuan , Li, Yarong , Byeon, Seul Kee , Pandey, Akhilesh , Bellen, Hugo J. , Pandey, Akhilesh , Bellen, Hugo J , Byeon, Seul Kee

Mayo Clinic

Science Advances | July 13, 2022 | Volume: 8 | Issue: 28 | Pages: No page available

10.1126/sciadv.abn3326 | PMID 35857503 Get It

Recessive variants in GBA1 cause Gaucher disease, a prevalent form of lysosome storage disease. GBA1 encodes a lysosomal enzyme that hydrolyzes glucosylceramide (GlcCer) into glucose and ceramide. Its loss causes lysosomal dysfunction and increased levels of GlcCer. We generated a null allele of the Drosophila ortholog Gba1b by inserting the Gal4 using CRISPR-Cas9. Here, we show that Gba1b is expressed in glia but not in neurons. Glial-specific knockdown recapitulates the defects found in Gba1b mutants, and these can be rescued by glial expression of human GBA1 . We show that GlcCer is synthesized upon neuronal activity, and it is transported from neurons to glia through exosomes. Furthermore, we found that glial TGF-β/BMP induces the transfer of GlcCer from neurons to glia and that the White protein, an ABCG transporter, promotes GlcCer trafficking to glial lysosomes for degradation.
Management Reasoning: Empirical Determination of Key Features and a Conceptual Model
Cook, David A. , Stephenson, Christopher R. , Gruppen, Larry D. , Durning, Steven J.

Mayo Clinic

Academic Medicine | July 13, 2022 | Volume: 98 | Issue: 1 | Pages: 80-87

10.1097/acm.0000000000004810 | PMID 35830267 Get It

Abstract Purpose Management reasoning is a critical yet understudied phenomenon in clinical practice and medical education. The authors sought to empirically identify key features of management reasoning and construct a model describing the management reasoning process. Method In November 2020, 4 investigators each reviewed 10 video clips of simulated outpatient physician–patient encounters and used a coding form to document key features and insights related to management reasoning. The team used a constant comparative approach to distill 120 pages of raw observations into an 18-page list of management tasks, processes, and insights. The team then had a series of discussions to iteratively refine these findings into a parsimonious model of management reasoning. Results The investigators empirically identified 12 distinct features of management reasoning: contrasting and selection among multiple solutions; prioritization of patient, clinician, and system preferences and constraints; communication and shared decision making; ongoing monitoring and adjustment of the management plan; dynamic interplay among people, systems, and competing priorities; illness-specific knowledge; process knowledge; management scripts; clinician roles as patient teacher and salesperson; clinician–patient relationship; prognostication; and organization of the clinical encounter (sequencing and time management). Management scripts seemed to play a prominent and critical role. The model of management reasoning comprised 4 steps: instantiation of a management script, identifying (multiple) options and beginning to teach the patient, shared decision making, and ongoing monitoring and adjustment. This model also conceives 2 overarching features: that management reasoning is personalized to the patient and that it occurs between individuals rather than exclusively within the clinician’s mind. Conclusions Management scripts constitute a key feature of management reasoning, along with teaching patients about viable options, shared decision making, ongoing monitoring and adjustment, and personalization. Management reasoning seems to be constructed and negotiated between individuals rather than exclusively within the clinician.
Costs of Physician Continuous Professional Development: A Systematic Review
Cook, David A. , Wilkinson, John M. , Foo, Jonathan , Foo, J

Mayo Clinic

Academic Medicine | July 13, 2022 | Volume: 97 | Issue: 10 | Pages: 1554-1563

10.1097/acm.0000000000004805 | PMID 35830262 Get It

Purpose An essential yet oft-neglected step in cost evaluations is the selection of resources (ingredients) to include in cost estimates. The ingredients that most influence the cost of physician continuous professional development (CPD) are unknown, as are the relative costs of instructional modalities. This study’s purpose was to estimate the costs of cost ingredients and instructional modalities in physician CPD. Method The authors conducted a systematic review in April 2020, searching MEDLINE, Embase, PsycInfo, and the Cochrane Library for comparative cost evaluations of CPD for practicing physicians. Two reviewers, working independently, screened articles for inclusion and extracted information on costs (converted to 2021 U.S. dollars) for each intervention overall, each ingredient, and each modality. Results Of 3,338 eligible studies, 62 were included, enumerating costs for 86 discrete training interventions or instructional modalities. The most frequently reported ingredients were faculty time (25 of 86 interventions), materials (24), administrator/staff time (23), and travel (20). Ingredient costs varied widely, ranging from a per-physician median of $4 for postage (10 interventions) to $525 for learner time (13); equipment (9) and faculty time were also relatively expensive (median > $170). Among instructional modalities (≤ 11 interventions per modality), audit and feedback performed by physician learners, computer-based modules, computer-based virtual patients, in-person lectures, and experiences with real patients were relatively expensive (median > $1,000 per physician). Mailed paper materials, video clips, and audit and feedback performed by others were relatively inexpensive (median ≤ $62 per physician). Details regarding ingredient selection (10 of 62 studies), quantitation (10), and pricing (26) were reported infrequently. Conclusions Some ingredients, including time, are more important (i.e., contribute more to total costs) than others and should be prioritized in cost evaluations. Data on the relative costs of instructional modalities are insightful but limited. The methods and reporting of cost valuations merit improvement.
Features of Idiopathic Intracranial Hypertension on MRI With MR Elastography: Prospective Comparison With Control Individuals and Assessment of Postintervention Changes
Murphy, Matthew C. , Bhatti, M. Tariq , Cutsforth‐Gregory, Jeremy K. , Chen, John J. , Chen, John J , Cogswell, Petrice M. , Madhavan, Ajay A. , Senjem, Matthew L. , Huston, John

Mayo Clinic

American Journal of Roentgenology | July 13, 2022 | Volume: 219 | Issue: 6 | Pages: 940-951

10.2214/ajr.22.27904 | PMID 35822642 Get It

Faculty Opinions recommendation of All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic.
Sharpe, Emily E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 13, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742218538.793593971 Get It

The landscape of metabolic brain alterations in Alzheimer's disease
Batra, Richa , Arnold, Matthias , Wörheide, Maria A. , Allen, Mariet , Wang, Xue , Blach, Colette , Levey, Allan I. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Krumsiek, Jan , Krumsiek, Jan , Bennett, David A. , Arnold, Matthias , Levey, Allan I , Kastenmüller, Gabi , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | July 13, 2022 | Volume: 19 | Issue: 3 | Pages: 980-998

10.1002/alz.12714 | PMID 35829654 Get It

Abstract Introduction Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD‐associated metabolic changes in the brain has been missing. Methods We metabolically profiled 500 samples from the dorsolateral prefrontal cortex. Metabolite levels were correlated with eight clinical parameters, covering both late‐life cognitive performance and AD neuropathology measures. Results We observed widespread metabolic dysregulation associated with AD, spanning 298 metabolites from various AD‐relevant pathways. These included alterations to bioenergetics, cholesterol metabolism, neuroinflammation, and metabolic consequences of neurotransmitter ratio imbalances. Our findings further suggest impaired osmoregulation as a potential pathomechanism in AD. Finally, inspecting the interplay of proteinopathies provided evidence that metabolic associations were largely driven by tau pathology rather than amyloid beta pathology. Discussion This work provides a comprehensive reference map of metabolic brain changes in AD that lays the foundation for future mechanistic follow‐up studies.
The relationship between insulin and glucagon concentrations in non‐diabetic humans
LAURENTI, MARCELLO C. , Arora, Praveer, Man, Chiara Dalla , Andrews, James C. , Rizza, Robert A., Matveyenko, Aleksey V. , Bailey, Kent R. , Vella, Adrian , Matveyenko, Aleksey, Vella, Adrian , Dalla Man, Chiara , Cobelli, Claudio

Mayo Clinic

Physiological Reports | July 13, 2022 | Volume: 10 | Issue: 13 | Pages: No page available

10.14814/phy2.15380 | PMID 35822422 Get It

Buprenorphine Waiver Attitudes Among Primary Care Providers
Lai, Benjamin , Croghan, Ivana T. , Ebbert, Jon O. , Croghan, Ivana T , Lai, Benjamin

Mayo Clinic

Journal of Primary Care & Community Health | July 13, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221112272 | PMID 35822763 Get It

Background: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise. In April 2021, the Department of Health and Human Services removed the mandatory training requirement to obtain a buprenorphine waiver; the goal was to encourage more providers to prescribe buprenorphine, thus improving access. Little is known about the attitudes on buprenorphine prescribing after this policy change. Objective: The primary objective was to assess attitudes among primary care providers toward the removal of the buprenorphine waiver training requirement. A secondary objective was to identify other barriers to prescribing buprenorphine. Methods: We conducted a survey between September 15 and October 13, 2021 to assess the overall beliefs on the effectiveness of MOUD and attitudes toward the removal of the waiver training, current knowledge of buprenorphine, current practice styles related to screening for and treating OUD, and attitudes toward prescribing buprenorphine in the future. This survey was sent to 890 Mayo Clinic primary care providers in 5 US states. Results: One hundred twenty-three respondents (13.8%) completed the survey; 35.8% respondents agreed that the removal of the waiver training was a positive step. These respondents expressed a greater familiarity with the different formulations, pharmacology, and titration of buprenorphine. This group was also more likely to prescribe (or continue to prescribe) buprenorphine in the future. Approximately one-third (34.4%) of respondents reported perceived institutional support in prescribing buprenorphine. This group expressed greater confidence in diagnosing OUD, had greater familiarity with the different formulations, pharmacology, and titration of buprenorphine, and was more likely to prescribe (or continue to prescribe) buprenorphine in the future. Respondents who have been in practice for 11 to 20 years since completion of training were most likely to refer all OUD patients to specialists. Conclusions: Results of our survey suggests that simply removing the mandatory waiver training requirement is insufficient in positively changing attitudes toward buprenorphine prescribing. A key barrier is the perceived lack of institutional support. Future studies investigating effective ways to provide such support may help improve providers’ willingness to prescribe buprenorphine.